Fake it till you fund it? Silicon Valley investment gurus have long promoted the idea that startups should ‘fake it till you make it’ to become […] May 24, 2023 · V-Bio Ventures
V-Bio Ventures portfolio company Dualyx raises €40 million to progress Treg therapies for autoimmune diseases into the clinic Use of proceeds will enable the development of the Company’s lead autoimmune program DT-001, targeting TNFR2, as well as its […] May 15, 2023 · V-Bio Ventures
Potential impact of the corona crisis on the life sciences industry Over the past few months, every news headline has focused on COVID-19. The industry is accelerating its own in-house research […] March 26, 2020 · V-Bio Ventures
Cell therapies: opportunities and challenges Recent activities in the cell therapy field have prompted many investment funds to pour fresh and increasing capital into this […] May 5, 2020 · V-Bio Ventures
VIB: the driving force behind a booming biotech ecosystem Since VIB was established, the world class research institute has been led by a duo of managing directors. As Johan […] July 7, 2020 · BioVox
Building bigger for Belgium’s maturing biotech scene Biotech is booming in Belgium. To support the evolving needs of this world-class ecosystem, the Mariën family initiated and are […] July 7, 2020 · Turnstone Communications
Anacura, a Belgian biotech company, sells stem cell business to Boehringer Ingelheim Ghent, Belgium, 27 July 2020 – GST, the stem cell specialist for horses and pets within the Anacura Group, has […] July 27, 2020 · Turnstone Communications
V-Bio invests into ExeVir Bio to accelerate development of new treatment conferring broad protection against Covid-19 Ghent, Belgium, 28 July 2020 – Today V-Bio Ventures announces its investment in a EUR 23 million Series A financing into ExeVir Bio. […] July 28, 2020 · V-Bio Ventures
Newton Biocapital I invests in J-Pharma Co., Ltd. in Japan focusing on drug development targeting L-type Amino Acid Transporter 1 (LAT1) for cancer and autoimmune diseases Brussels, Belgium / Tokyo, Japan – 27 August 2020 – Newton Biocapital I (“Newton”), an investment company in life sciences, […] August 27, 2020 · Turnstone Communications
Biodol Therapeutics receives EUR 4.5 million to progress its novel pain medication in a Series A led by V-Bio Ventures V-Bio Ventures, a leading Belgian life sciences VC, invests in Biodol Therapeutics, a French biotech specialized in next-generation chronic pain […] August 31, 2020 · V-Bio Ventures
Belgian stem cell company GST bought by German pharmaceutical giant The German pharmaceutical giant Boehringer Ingelheim has acquired GST, a stem cell specialist based in Belgium. A part of the […] August 31, 2020 · Turnstone Communications
Countering COVID-19 with llama antibodies In July 2020, VIB spin-off ExeVir Bio raised €23 million to advance a llama-derived antibody against COVID-19. The company is […] August 31, 2020 · BioVox
Belgium: the number one biotech country in Europe! For the third year in a row, Belgium has been ranked the number one country in Europe for biotech! Belgium […] September 30, 2020 · BioVox
V-Bio Ventures invests in new start-up Animab in a EUR 3.4 million Seed Financing to improve health and performance of livestock animals Gent, Belgium, 27 October 2020 – Today V-Bio Ventures announces its investment in Animab, a new venture spin-off from VIB, in a EUR […] October 27, 2020 · V-Bio Ventures
Newton Biocapital I invests in Perseus Proteomics Inc. in Japan to develop therapeutic antibodies for the treatment of blood cancers Brussels, Belgium / Tokyo, Japan – 1 December 2020 – Newton Biocapital I (“Newton”), a life sciences investment fund active in Europe […] December 1, 2020 · Turnstone Communications